The introduction of antimicrobial agents in resource-constrained countries: Impact on the emergence of resistance

Antimicrobial Resistance in Developing Countries

Volumn 9780387893709, Issue , 2010, Pages 59-71

  Franco Paredes, Carlos ^a,b   Santos Preciado, Jose Ignacio ^c  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902544188     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-89370-9_5     Document Type: Chapter

References (43)

1. Akileswaran, C., Lurie, M. N., Flanigan, T. P., and Mayer, K. H. 2005. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin. Infect. Dis. 41:376-385.
2. Bagchi, S., Kempf, M. C., Westfall, A. O., Maherya, A., Willig, J., and Saag, M. S. 2007. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin. Infect. Dis. 44:135-138.
3. Barnes, K. I., and White, N. J. 2005. Population biology and antimalarial resistance: The transmission of malaria drug resistance in Plasmodium falciparum. Acta Trop. 94:230-240.
4. Byarugaba, D. K. 2004. A view on antimicrobial resistance in developing countries and responsible risk factors. Int. J. Antimicrob. Agents 24:105-110.
5. Byarugaba, D. K. 2005. Antimicrobial resistance and its containment in developing countries. In Antibiotic policies: Theory and practice, ed. I. M. Gould, and J. W. M. van der Meer, pp. 617-647. New York: Kluwer Academic/Plenum Publishers.
6. Corea, E., de Silva, T., and Perera, J. 2003. Methicillin-resistant Staphylococcus aureus: Prevalence, incidence and risk factors associated with colonization in Sri Lanka. J. Hosp. Infect. 55:145-148.
7. Duse, A. G. 1998. Antibiotic resistance in developing countries. In Infection control practices, ed. A. Emerson, and M. Arrowsmith, pp. 38-44. Borken, Germany: 3 M Medical Markets Laboratory.
8. Dromigny, J. A., and Perrier-Gros-Claude, J. D. 2003. Antimicrobial resistance of Salmonella enterica serotype Typhi in Dakar, Senegal. Clin. Infect. Dis. 37:465-466.
9. Dye, C., Williams, B. G., Espinal, M. A., and Raviglione, M. C. 2002. Erasing the world's slow stain: Strategies to beat multidrug-resistant tuberculosis. Science 295:2042-2046.
10. Franco-Paredes, C., Jones, D., Rodriguez-Morales, A. J., and Santos-Preciado, J. I. 2007. Improving the health of neglected populations in Latin America. BMC Public Health 7:11. DOI: 10.1186/1471-2458-7-11.
11. Gallant, J. E. 2007. Drug resistance after failure of initial antiretroviral therapy in resourcelimited countries. Clin. Infect. Dis. 44:453-455.
12. Hadi, U., Kolopaking, E. P., Gardjito, W., Gyssens, I. C., and van den Broek, P. J. 2006. Antimicrobial resistance and antibiotic use in low-income and developing countries. Folia Medica Indonesiana, 42:183-195.
13. Hart, C. A., and Kariuki, S. 1998. Antimicrobial resistance in developing countries. Br. Med. J. 317:647-650.
14. Huebner, R. E., Wasas, A. D., and Klugman, K. P. 2000. Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fluid isolates of Streptococcus pneumoniae in South Africa, 1991-1998. Int. J. Infect. Dis. 4:214-218.
15. Iseman, M. D. 2007. Extensive drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand. Clin. Infect. Dis. 45:1415-1416.
16. Jabeen, K., Khan, E., and Hasan, R. 2006. Emergence of quinolone-resistant Neisseria gonorrhoeae in Pakistan. Int. J. STD AIDS. 17(1):30-33.
17. Jorgensen, J. H., Crawford, S. A., and Fiebelkorn, K. R. 2005. Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J. Clin. Microbiol. 43:3162-3171.
18. Kauser, J., Khan, E., and Hasan, R. 2006. Emergence of quinolone-resistant Neisseria gonorrhoeae in Pakistan. Int. J. STD AIDS 17:30-34.
19. Kurle, S. N., Gangakhedkar, R. R., Sen, S., Hayatnagarkar, S. S., Tripathy, S. P., and Paranjape, R. S. 2007. Emergence of NNRT drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India. AIDS Res. Hum. Retroviruses 23:682-685.
20. Lazzari, S., de Felici, A., Sobel, H., and Bertagnolio, S. 2004. HIV drug resistance surveillance: Summary of an April 2003 WHO Consultation. AIDS 18(suppl 3):S49-S53.
21. Laxminarayan, R., and Weitzman, M. L. 2002. On the implications of endogenous resistance to medications. J. Health Econ. 21:709-718.
22. Laxminarayan, R., and Weitzman M. L. 2003. Value of treatment heterogeneity for infectious diseases. In Battling resistance to antibiotics and pesticides: An economic approach. ed. R. Laxminarayan, pp 63-75. Washington, DC: Resources for the Future.
23. Livermore, D. M. 2007. Introduction: The challenge of multiresistance. Int. J. Antimicrob. Agents 29(suppl 3):S1-S7.
24. Lon, C. T., Tsuyuoka, R., Phanouvong, S., Nivanna, N., Socheat, D., Sokhan, C., Blum, N., Christophel, E. M., and Smine, A. 2006. Counterfeit and substandard antimalarial drugs in Cambodia. Trans. R. Soc. Trop. Med. Hyg. 100:1019-1024.
25. Moellering, R. C. Jr. 1998. Antibiotic resistance: Lessons for the future. Clin. Infect. Dis. 27(suppl 1):S135-S140.
26. Newton, P., Proux, S., Green, M., Smithuis, F., Rozendaal, J., Prakongpan, S., Chotivanich, K., Mayxay, M., Looareesuwan, S., Farrar, J., Nosten, F., and White, N. J. 2001. Fake artesunate in Southeast Asia. Lancet 357:1948-1950.
27. Nosten, F., van Vugt, M., Price, R., Luxemberger, C., Thway, K. L., Brockman, A., McGready, A., ter Kuile, F., Looareesuwan, S., and White, N. J. 2000. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in Western Thailand: A prospective study. Lancet 356:297-302.
28. Okeke, I. N., Laxminarayan, R., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., Pablos-Mendez, A., and Klugman, K. P. 2005a. Antimicrobial resistance in developing countries. Part 1: Recent trends and current status. Lancet 5:481-493.
29. Okeke, I. N., Klugman, K. P., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., Pablos-Mendez, A., and Laxminarayan, R. 2005b. Antimicrobial resistance in developing countries. Part II: Strategies for containment. Lancet 5:568-580.
30. Parry, C. M., Duong, N. M., Zhou, J., Hoang Mai, N. T., Diep, T. S., Thinh, L. Q., Wain, J., Van Vinh Chau, N., Griffings, D., Day, N. P., White, N. J., Hien, T. T., Spratt, B. G., and Farrar, J. J. 2002. Emergence in Vietnam of Streptococcus pneumoniae resistant to multiple antimicrobial agents as a result of dissemination of the multiresistant Spain 23F-1 clone. Antimicrob. Agents Chemother. 46:3512-3517.
31. Pillay, M., and Sturm, A. W. 2007. Evolution of the extended drug-resistant F15/LAM4/KXZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45:1409-1414.
32. Ray, K., Bala, M., Kumar, J., and Misra, R. S. 2000. Trend of antimicrobial resistance in Neisseria gonorrhoeae at New Delhi, India. Int. J. STD AIDS 11:115-118.
33. Rhem, S. J., and Weber, T. 2007. The far-reaching impact of antimicrobial resistance. Clin. Infect. Dis. 45:S97-S98.
34. Riley, L. W., Ko, A. I., Unger, A., and Reis, M. G. 2007. Slum health: Diseases of neglected populations. BMC Int. Health Hum. Rights 7:2.
35. Sabir, N., Khan, E., Sheikh, L., and Hasan, R. 2004. Impact of antibiotic usage on resistance in microorganisms; urinary tract infections with E. coli as a case in point. J. Pak. Med. Assoc. 54:472-475.
36. Selgelid, M. J., Kelly, P. M., and Sleigh A. 2008. Ethical challenges in TB control in the era of XDR-TB. Int. J. Tuberc. Lung Dis. 12:231-235.
37. Shekelle, P., Maglione, M., Geotz, M. B., Wagner, G., Wang, Z., Hilton, L., Carter, J., Chen, S., Tringle, C., Mojica, W., and Newberry, S. 2007. Antiretroviral (ARV) drug resistance in the developing world. Evid. Rep. Technol. Assess. 156:1-74.
38. Sirinavin, S., and Dowell, S. F. 2002. Antimicrobial resistance in countries with limited resources: Unique challenges and limited alternatives. Semin. Pediatr. Infect. Dis. 15:94-98.
39. Sungkanuparaph, S., Manosuthi, W., Kiertiburanakul, S. Piyavong, B., Chumpathat, N., and Chantratita, W. 2007. Options for a second-line antiretroviral regimen for HIV type-1 infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine falls. Clin. Infect. Dis. 44:447-452.
40. Tupasi, T. E. 1999. Quinolone use in the developing world. Drugs 58(Supp. 2):55-59.
41. Vaypayee, M., Kaushik, S., Mojumdar, K., and Sreenivas, V. 2007. Antiretroviral treatment in resource-poor settings: A View from India. Indian J. Med. Sci. 61:390-397.
42. WHO 2001. WHO Global strategy for containment of antimicrobial resistance. Geneva, Switzerland: World Health Organization.
43. Weller I (2007). Delivery of antiretroviral therapy in Sub-Saharan Africa. Clin. Infect Dis. 43:777-778.